What question did this study set out to answer?

This study aims to evaluate the feasibility and diagnostic accuracy of a hybrid 99mTc–ICG tracer for sentinel lymph node mapping in early-stage epithelial ovarian cancer.

June 19, 2026CancersOpen Access

Hybrid 99mTc–ICG Sentinel Lymph Node Mapping in Apparent Early-Stage Epithelial Ovarian Cancer: A First Prospective Evaluation of a True Molecular Hybrid Tracer (HibrOv Trial)

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the feasibility and diagnostic accuracy of a hybrid 99mTc–ICG tracer for sentinel lymph node mapping in early-stage epithelial ovarian cancer.
Prospective observational study at a tertiary oncology center from 2021 to 2026
Patients with suspicious ovarian masses or requiring restaging underwent SLN mapping using a hybrid tracer
SLNs identified using gamma detection and near-infrared fluorescence imaging.
SLN detection rate was 92.5% overall, 100% in malignant cases
15% of malignant tumors had metastatic SLNs detected, with a false-negative rate of 0%
Sensitivity and negative predictive value were both 100%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective trial evaluates diagnostic accuracy of hybrid tracer in early-stage epithelial ovarian cancer, suggesting potential for less invasive lymphatic assessment.

Cite This Study

Amengual et al. (2026) studied this question.

synapsesocial.com/papers/6a34de9d65a5b0777af2de6c https://doi.org/10.3390/cancers18121973

View Full Paper

Ask AI

Bookmark

Implication

Prospective trial evaluates diagnostic accuracy of hybrid tracer in early-stage epithelial ovarian cancer, suggesting potential for less invasive lymphatic assessment.

Hybrid 99mTc–ICG Sentinel Lymph Node Mapping in Apparent Early-Stage Epithelial Ovarian Cancer: A First Prospective Evaluation of a True Molecular Hybrid Tracer (HibrOv Trial)

Key Points

Discussion

Implication

Cite This Study

Hybrid 99mTc–ICG Sentinel Lymph Node Mapping in Apparent Early-Stage Epithelial Ovarian Cancer: A First Prospective Evaluation of a True Molecular Hybrid Tracer (HibrOv Trial)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider